Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 21;31(11):1909-1925.e7.
doi: 10.1016/j.chembiol.2024.10.003. Epub 2024 Nov 1.

A LANA peptide inhibits tumor growth by inducing CHD4 protein cleavage and triggers cell death

Affiliations

A LANA peptide inhibits tumor growth by inducing CHD4 protein cleavage and triggers cell death

Hiroki Miura et al. Cell Chem Biol. .

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) establishes a latent infection, and viral genes are poised to be transcribed in the latent chromatin. In the poised chromatins, KSHV latency-associated nuclear antigen (LANA) interacts with cellular chromodomain-helicase-DNA-binding protein 4 (CHD4) and inhibits viral promoter activation. CHD4 is known to regulate cell differentiation by preventing enhancers from activating promoters. Here, we identified a putative CHD4 inhibitor peptide (VGN73) from the LANA sequence corresponding to the LANA-CHD4 interaction surface. The VGN73 interacts with CHD4 at its PHD domain with a dissociation constant (KD) of 14 nM. Pre-treatment with VGN73 enhanced monocyte differentiation into macrophages and globally altered the repertoire of activated genes in U937 cells. Furthermore, the introduction of the peptide into the cancer cells induced caspase-mediated CHD4 cleavage, triggered cell death, and inhibited tumor growth in a xenograft mouse model. The VGN73 may facilitate cell differentiation therapy.

Keywords: CHD4; KSHV; LANA; apoptosis; autophagy; cancer; cell differentiation; leukemia; monocyte; peptide.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests H.M., K.-H.W., and Y.I. filed provisional patents related to the VGN73 peptides utilization for therapeutics purposes through University of California Davis. M.S. and Y.I. are founders of VGN Bio, Inc. and are planning to further develop VGN73 as therapeutics tools.

References

    1. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, and Moore PS (1994). Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266, 1865–1869. 10.1126/science.7997879. - DOI - PubMed
    1. Schalling M, Ekman M, Kaaya EE, Linde A, and Biberfeld P (1995). A role for a new herpes virus (KSHV) in different forms of Kaposi’s sarcoma. Nat Med 1, 707–708. 10.1038/nm0795-707. - DOI - PubMed
    1. Cesarman E, Chang Y, Moore PS, Said JW, and Knowles DM (1995). Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332, 1186–1191. 10.1056/NEJM199505043321802. - DOI - PubMed
    1. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, and Knowles DM (1996). Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood 88, 645–656. - PubMed
    1. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d’Agay MF, Clauvel JP, Raphael M, Degos L, and et al. (1995). Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 86, 1276–1280. - PubMed

MeSH terms

LinkOut - more resources